COMPARATIVE STUDY OF CLINICAL SAFETY OUTCOME OF NEOADJUVANT INTRAVESICAL MITOMYCIN-C THERAPY IMMEDIATELY BEFORE TRANSURETHRAL RESECTION OF BLADDER TUMOR VS PERIOPERATIVE INTRAVESICAL MITOMYCIN-C IN PATIENTS WITH NONMUSCLE-INVASIVE BLADDER CANCER
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: This study aims to compare the outcome and complications of adjuvant vs neoadjuvant IMMC (intravesical mitomycin C) for non-muscle-invasive bladder cancer (NMIBC). Material & Methods: This prospective randomized observational study was conducted from June 2023 to December 2024. Sixty-two patients with clinico-radiological evidence of bladder growth were randomized into two arms: Neoadjuvant IMMC and Perioperative IMMC. Results: Immediate complications were more frequent in Group B, with significantly higher dysuria, suprapubic pain (74.2% vs 32.3%), and febrile UTIs (29% vs 3.2%). Haematuria was also more common in Group B (58.1%). Early complications showed similar trends: dysuria (51.6% vs 19.4%), haematuria (45.2% vs 19.4%), and bladder changes (23.3% vs 0%) were more prevalent in Group B. Allergic reactions were slightly lower in Group B (6.5%) than in Group A (9.7%). Conclusion: Pre-operative MMC instillation was more effective in reducing recurrence and improving resection ease, with fewer complications. Perioperative MMC was associated with increased inflammation and adverse events. Pre-TURBT MMC is recommended for improved clinical outcomes, while peri-operative MMC may be considered for select low-risk patients. Keywords: Complication, IMMC, bladder cancer.
##plugins.themes.bootstrap3.article.details##
Complication, IMMC, bladder cancer.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021 May;71(3):209-49.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. European Urology. 2017 Jan 1;71(1):96-108.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov;68(6):394- 424.
International Agency for Research on Cancer. Cancer Today. Data visualization tools for exploring the global cancer burden in 2020. Available online: Gco. iarc. fr (accessed on 24 September 2020). 2018.
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. European urology. 2013 Feb 1;63(2):234-41.
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BW, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update. European urology. 2019 Nov 1;76(5):639-57.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer. 2019 Apr 15;144(8):1941-53.
Besarani D, AL‐AKRAA MA. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU international. 2006 Jul;98(1):232-3.
Lim D, Izawa JI, Middlebrook P, Chin JL. Bladder perforation after immediate postoperative intravesical instillation of mitomycin C. Canadian Urological Association Journal. 2010 Feb;4(1):E1.
El Azab A, Abdelbary A, Aly El Faqeh MO, Aboulkassem H, Zaghloul AS, Karkeet RM et al. The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette–Guérin versus BCG alone in non-muscle- invasive bladder cancer: A randomized controlled trial. Investigative and Clinical Urology. 2023 Oct 25;64(6):554.
Saarinen P. The Usage of The Paris Classification System in Urine Cytology in the Diagnosis of Non-invasive Bladder Cancer: A Retrospective Single-Center Study.
Mostafid AH, Rajkumar RG, Stewart AB, Singh R. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. BJU international. 2006 Mar;97(3):509-12.
Chen L, Li J, Zhang Z, et al. The Efficacy of Perioperative Mitomycin C in Non- Muscle Invasive Bladder Cancer. Urology. 2015;85(5):1125-1131.
Kamat AM, Shabsigh A, Gee J, et al. Intravesical Mitomycin-C: A Review of Its Clinical Use in Non-Muscle-Invasive Bladder Cancer. Eur Urol. 2011;60(2):303-310.
Motte S, Lallemand D, d'Anvers S, et al. Impact of Intravesical Mitomycin C on Complications After Transurethral Resection of Bladder Tumors. J Urol. 2014;192(4):1037-1043.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. The role of intravesical mitomycin C in preventing recurrence and progression of non-muscle invasive bladder cancer: A systematic review and meta-analysis. Eur Urol. 2006;49(2):173- 178.
Mostafid AH, Porta N, Cresswell J, Griffiths TRL, Kelly JD, Penegar SR et al. CALIBER: A phase II randomized feasibility trial of chemoablation with mitomycin- C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int. 2020;125(5):817-826.
Manfredi C, Spirito L, Calace FP, Balsamo R, Terribile M, Stizzo M, Romano L, Napolitano L, Califano G, Cirillo L, Fusco GM, Rosati C, Quattrone C, Sciorio C, Creta M, Longo N, De Sio M, Arcaniolo D. Oral Preparation of Hyaluronic Acid, Chondroitin Sulfate, Curcumin, and Quercetin (Ialuril® Soft Gels) for the Prevention of LUTS after Intravesical Chemotherapy. Pathophysiology. 2022 Jul 13;29(3):365-373. doi: 10.3390/pathophysiology29030028. PMID: 35893598; PMCID: PMC9326532.
Nieder AM, Smith TM, Wrobel W. Comparison of immediate versus delayed intravesical mitomycin-C instillation in patients undergoing TURBT: A randomized controlled trial. BJU Int. 2021;128(1):25-31.
Sharma P, Gupta S. A meta-analysis of the role of intravesical mitomycin-C in the prevention of recurrence of non-muscle-invasive bladder cancer after TURBT. J Urol. 2020;204(2):243-50.
Cheng H, Zeng X, Zhang G. The efficacy of intravesical mitomycin-C in preventing recurrence of non-muscle invasive bladder cancer: Immediate versus perioperative administration. Cancer Med. 2019;8(7):3487-96.